BEVERLY, MA--(Marketwire - June 3, 2010) - Cellceutix Corporation (
In the interview, Mr. Ehrlich discusses the progressions of KM-391, Cellceutix's compound for the treatment of autism, and Kevetrin, their drug being developed as a treatment for drug-resistant cancers. Mr. Ehrlich explained why their autism drug is revolutionary as there is no drug available today for the treatment of autism. Additionally, Mr. Ehrlich also discusses the company's growth strategy as it relates to future potential partnerships, shareholder value and the strength of the Cellceutix management team.
"We are not dealing with just another cancer drug; we have indications that it is effective against drug-resistant cancers, which is a multibillion dollar market," Mr. Ehrlich explained. "Most cancer drugs currently out there are just another variation of existing cancer drugs, whether they be another platinum based drug or another Taxol. We, however, have a completely new and novel compound."
"We are pleased to have been interviewed by CEOCFO. The interview provides us another opportunity to showcase to our shareholders the many milestones we are achieving and the progressions of our business strategy," commented Mr. Ehrlich.
The interview is available at:
http://www.cellceutix.com/CTIX-Cellceutix10-RLO-Changes-Color.pdf
About CEOCFO Interviews & News
CEOCFO Interviews & News is a weekly print online publication, marketing engine featuring publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX, OTC: BB, Pink Sheets) and Canadian (TSX & TSX-V) stock exchanges, Investment & Money Management Ideas.
About Cellceutix
Cellceutix Corporation is a preclinical cancer and anti-inflammatory drug developer. Cellceutix owns the rights to eight drug compounds, including Kevetrin™, which it is developing as a treatment for certain cancers, and KM-391, which it is developing for the treatment of autism. More information is available on the Cellceutix web site at www.cellceutix.com.
This Press Release contains forward-looking statements that are based on our current expectations, beliefs and assumptions about the industry and markets in which Cellceutix Corporation operates. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause Cellceutix's actual results to be materially different from any future results expressed or implied by these statements. Actual results may differ materially from what is expressed in these statements, and no assurance can be given that Cellceutix can successfully implement its core business strategy and improve future earnings.
The factors that may cause Cellceutix's actual results to differ from its forward-looking statements include: Cellceutix's current critical need for additional cash to sustain existing operations and meet ongoing existing obligations and capital requirements; Cellceutix's ability to implement its new product development and commercialization, enter into clinical trials, expand the intellectual property portfolio, and receive regulatory approvals in a timely and cost-effective manner. All forward-looking statements are also expressly qualified in their entirety by the cautionary statements included in Cellceutix's SEC filings, including its quarterly reports on Form 10-Q and its annual report on Form 10-K.
Kevetrin and KM-391 have not been studied in humans at this time. The Company's positive results in animal studies do not necessarily guarantee success in humans, though they may form the basis for beginning Phase 1 trials.
Contact Information:
Contact:
Cellceutix Corp.
Leo Ehrlich
CFO
(978) 633-3623